Loading company details...
Beta
Latest Form 4 (Oct 8, 2025): Michael Klichinsky (Chief Scientific Officer): Exercise/Conversion of 56,982 shares, $6.3K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 8, 2025 | Michael Klichinsky, Chief Scientific Officer | Exercise/Conversion | 56,982 | $6.3K |
| Oct 3, 2025 | Michael Klichinsky, Chief Scientific Officer | Sale | 165,000 | $42.4K |
| Jan 30, 2025 | Michael Klichinsky, Chief Scientific Officer | Grant/Award | 221,000 | n/a |
| Jan 30, 2025 | Steven Kelly, President and CEO | Grant/Award | 500,000 | n/a |
| Nov 1, 2024 | Sohanya Roshan Cheng | Grant/Award | 38,700 | n/a |
| Jul 1, 2024 | Marella Thorell | Grant/Award | 38,700 | n/a |
| Jul 1, 2024 | David Scadden | Grant/Award | 38,700 | n/a |
| Jun 27, 2024 | Sanford S. Zweifach | Grant/Award | 19,350 | n/a |
| Jun 27, 2024 | Briggs Morrison | Grant/Award | 19,350 | n/a |
| Jun 27, 2024 | John Hohneker | Grant/Award | 19,350 | n/a |